Document Detail

Perception and quality of life associated with the use of olopatadine 0.2% (Pataday) in patients with active allergic conjunctivitis.
MedLine Citation:
PMID:  18165204     Owner:  NLM     Status:  MEDLINE    
This 28-d, open-label, multicenter, single-arm clinical study was designed to evaluate perceptions of olopatadine 0.2% in patients with active ocular allergic signs and symptoms. The study enrolled 330 patients, 5 to 94 y of age, who had previously used olopatadine 0.1% for active allergic conjunctivitis. Most patients were white (n=230; 70.1%) and female (n=239; 72.9%). Of all enrolled patients, 328 were evaluable for analysis. Throughout the study, patients instilled 1 drop of olopatadine 0.2% into each eye once daily; adverse events were documented and ocular evaluations were conducted to ensure patient safety. Direct evaluations of efficacy were not performed. On days 1 and 7, patients completed the Rhinoconjunctivitis Quality of Life Questionnaire, recorded their perceptions of olopatadine 0.1% (day 1) or 0.2% (day 7), and had their ocular allergies assessed globally. On each of the first 6 d of treatment, patients also completed a telephone-based perception questionnaire. On day 28, patients returned to the study center, reported their treatment perceptions, had their ocular allergies assessed, and exited the trial. Overall, patients had a positive perception of olopatadine 0.2%. Patients were more satisfied with olopatadine 0.2% than they remembered being with olopatadine 0.1% (289 vs 257 patients; 87.6% vs 77.8%; P<.05). The majority of the 48 patients who wore contact lenses (n=42; 88%) believed that they could wear their contacts as desired. Significant improvement was noted in all categories of the Rhinoconjunctivitis Quality of Life Questionnaire (P<.0001). No unexpected safety findings were reported. Patients perceived olopatadine 0.2% to be effective and well tolerated.
Stephen V Scoper; Gregg J Berdy; Steven J Lichtenstein; Jay M Rubin; Marc Bloomenstein; Robert E Prouty; Cullen T Vogelson; Michael R Edwards; Curtis Waycaster; Terri Pasquine; Robert D Gross; Stella M Robertson
Related Documents :
3360334 - Fusion ability lost and regained in visual adults.
6509404 - Follow-up study of electronystagmographic findings in friedreich's ataxia patients and ...
18402294 - Orbital pseudotumor: clinical features and outcomes.
2748124 - The influence of superficial epithelial keratopathy on the corneal endothelium.
21560154 - Detrusor after-contraction is associated with bladder outlet obstruction.
25469144 - Prediction of resistance to standard intravenous immunoglobulin therapy in kawasaki dis...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Advances in therapy     Volume:  24     ISSN:  0741-238X     ISO Abbreviation:  Adv Ther     Publication Date:    2007 Nov-Dec
Date Detail:
Created Date:  2007-12-31     Completed Date:  2008-04-09     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8611864     Medline TA:  Adv Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1221-32     Citation Subset:  T    
Virginia Eye Consultants, Norfolk, Virginia 23507, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Disease
Aged, 80 and over
Anti-Allergic Agents / therapeutic use*
Child, Preschool
Conjunctivitis, Allergic / drug therapy*,  psychology
Dibenzoxepins / therapeutic use*
Middle Aged
Patient Satisfaction
Quality of Life*
Reg. No./Substance:
0/Anti-Allergic Agents; 0/Dibenzoxepins; 113806-05-6/olopatadine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of insulin sensitivity on SHBG levels in premenopausal versus postmenopausal obese women.
Next Document:  Probrain natriuretic peptide for assessment of efficacy in heart failure treatment.